Fitzsimon_menu

Filter by

Atara Biotherapeutics
News | Jul 17, 2024

Atara Biotherapeutics

Today Atara announced that the FDA has accepted its Biologics License Application (BLA) and granted Priority Review with a January 15, 2025 hashtag#PDUFA date for tabelecleucel (tab-cel®) as monotherapy for treatment of adult and pediatric patients two years of age and older with Epstein-Barr virus (hashtag#EBV) positive post-transplant lymphoproliferative disease (hashtag#PTLD) who have received at least one prior therapy. For solid organ transplant patients, prior therapy includes chemotherapy unless chemotherapy is inappropriate. If approved, tab-cel would be the first approved therapy in the U.S. for EBV+ PTLD. Read the press release for more: https://bit.ly/46bainx

DARTNet enhances and enlarges clinical decision support for clinicians
News | Jul 03, 2024

DARTNet enhances and enlarges clinical decision support for clinicians

DARTNet leaders Wilson Pace and John Westfall co-author "An Exploratory Study of Physician Decision-Making When Treating Uncontrolled COPD" in International Journal of Chronic Obstructive Pulmonary Disease.

Companies selected to present at CBSA’s 2024 Rocky Mountain Life Sciences Investor & Partnering Conference
News | Jul 02, 2024

Companies selected to present at CBSA’s 2024 Rocky Mountain Life Sciences Investor & Partnering Conference

Congratulations to the startup, emerging, and growth companies selected to present at CBSA’s 2024 Rocky Mountain Life Sciences Investor & Partnering Conference, chosen by a panel of experts. Shout out to Fitzsimons Innovation Community Members, EnteroTrack, GelSana, RheumaGen, and Vona Oncology. among those selected.

Charles River Laboratories Announces Strategic Lentiviral Vector Manufacturing Collaboration with Gates Institute
News | Jul 01, 2024

Charles River Laboratories Announces Strategic Lentiviral Vector Manufacturing Collaboration with Gates Institute

Charles River Laboratories International, Inc. (NYSE: CRL) and the Gates Institute at the University of Colorado Anschutz Medical Campus today announced a lentiviral vector contract development and manufacturing organization (CDMO) agreement. Gates Institute will leverage Charles River’s premier cell and gene therapy CDMO expertise to develop Good Manufacturing Practice (GMP)-grade lentiviral vectors (LVVs) for use in novel chimeric antigen receptor (CAR) T-cell therapies for hematological cancers.

Colorado Tech Blog Features GelSana’s Innovative Materials
News | Jul 01, 2024

Colorado Tech Blog Features GelSana’s Innovative Materials

Colorado Tech Spotlight features a profile of GelSana and how this Fitzsimons Innovation Community company is disrupting the field of wound care. Discover how it works, the story behind it, and how the Colorado life sciences and medical technology community comes together to collaborate and grow our state's prominence in the field.

Paving the Way Toward Transplantation: NIH Awards Support Ophthalmology Retinal Research
News | Jun 26, 2024

Paving the Way Toward Transplantation: NIH Awards Support Ophthalmology Retinal Research

CellSight researchers have been granted funding from the National Institutes of Health to better understand retinal cells differentiation and mechanisms for successful stem cell-derived 3D retinal transplants in patients with age-related macular degeneration (AMD).

Expanding the Vision for Fitzsimons Innovation Community
News | Jun 10, 2024

Expanding the Vision for Fitzsimons Innovation Community

Fitzsimons Innovation Community is expanding life sciences innovation in the region with an updated mater plan for the 184-acre innovation campus to the north of the world-renowned University of Colorado Anschutz Medical Center. The innovation community is currently home to more than 80 visionary companies taking their research to the next level to cure disease, save lives and improve care. Centrally located within 20 minutes of Denver International Airport, downtown Denver and the Denver Tech Center, Fitzsimons Innovation Community is custom-built for discovery with state-of-the-art facilities and flex spaces, opportunities for strategic partnerships and collaboration, a broad range of community amenities and the best of the Colorado lifestyle.

Lohocla Research Announces FDA Clearance of Investigational New Drug Application for Kindolor, a Novel Medicinal Molecule for Treating Chronic Pain
News | May 30, 2024

Lohocla Research Announces FDA Clearance of Investigational New Drug Application for Kindolor, a Novel Medicinal Molecule for Treating Chronic Pain

Focusing on non-addictive treatments for chronic pain and addiction, Lohocla Research Corporation gets the go-ahead for first-in-human trials of their first-in-class therapeutic for chronic pain syndromes.

Colorado: Fueling the Future of Life Sciences
News | May 22, 2024

Colorado: Fueling the Future of Life Sciences

A group of 22 partners representing Colorado’s life sciences ecosystem have banded together to fund a new national economic development campaign to bolster Colorado into “America’s epicenter for life sciences innovation.”

CREJ Features Insights from April Giles on Choosing an Innovation Community
News | Apr 16, 2024

CREJ Features Insights from April Giles on Choosing an Innovation Community

For health care and life sciences companies beginning the search for a new facility to call home, innovation communities are often sought-after destinations.

GelSana Awarded an AFWERX Phase II SBIR Contract to Develop Novel Polymers for Enhanced Wound Healing in Combat-Related Burn Injuries
News | Apr 11, 2024

GelSana Awarded an AFWERX Phase II SBIR Contract to Develop Novel Polymers for Enhanced Wound Healing in Combat-Related Burn Injuries

GelSana, a Fitzsimons Innovation Community member company, will focus their efforts on the development of novel wound dressing polymers for the care of combat-related burn injuries.

EnteroTrack selected for prestigious cancer accelerator program
News | Apr 08, 2024

EnteroTrack selected for prestigious cancer accelerator program

Announced on the stage at ViVE 2024, EntroTrack was selected for the inaugural cohort from a robust list of startup applicants aiming to reduce the burden of cancer for all people.